Contra-indicated in patients with a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days; severe hypertension not adequately controlled on antihypertensive therapy; major surgery within the preceding 6 weeks; history of stroke within 30 days or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb/IIIa inhibitor; or dependency on renal dialysis.
- TRADE NAME: Integrilin (Merck)
- INDICATIONS: Acute coronary syndrome, unstable angina
- CLASS: Antiplatelet (antithrombotic), Glycoprotein IIb/IIIa inhibitor
- HALF-LIFE: 2.5 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticoagulants, Antiplatelet agents, Collagenase, Dasatinib, Drotrecogin Alfa, Fondaparinux, Glucosamine, Ibritumomab, Iloprost, Lepirudin, NSAIDs, Pentoxifylline, Salicylates, Thrombolytic agents, Tositumomab & Iodine131
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of eptifibatide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/31/2024
